Dr. West Discusses Crizotinib in ALK-NSCLC Trial Results

H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington discusses crizotinib (Xalkori) in ALK-non-small cell lung cancer (NSCLC) trial results. He describes that the information presented at ASCO, both in 2011 and in 2010, only improved with time and as the test population got larger.

The FDA approved crizotinib August 26, 2011.